PHARMACOECONOMICS OF PIPERACILLIN TAZOBACTAM AND IMIPENEM-CILASTATIN IN THE TREATMENT OF PATIENTS WITH INTRAABDOMINAL INFECTIONS

被引：13

作者：

JHEE, SS ^{[1
]}

GILL, MA ^{[1
]}

YELLIN, AE ^{[1
]}

BERNE, TV ^{[1
]}

HESELTINE, PNR ^{[1
]}

APPLEMAN, MD ^{[1
]}

机构：

[1] UNIV SO CALIF,SCH PHARM,DEPT CLIN PHARM,LOS ANGELES,CA 90033

来源：

CLINICAL THERAPEUTICS | 1995年 / 17卷 / 01期

关键词：

D O I：

10.1016/0149-2918(95)80013-1

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Costs involved in using piperacillin 4 g/tazobactam 500 mg, given as intermittent intravenous infusions every 8 hours, were compared with those for imipenem/cilastatin 500 mg, given as intermittent intravenous infusions every 6 hours, for the treatment of patients with gangrenous or perforated appendicitis. A total of 88 patients were included in our cost analyses: 42 patients in the piperacillin/tazobactam group and 46 patients in the imipenem/cilastatin group. Durations (mean +/- SD) of antibiotic therapies were 7.8 +/- 3.3 days and 7.1 +/- 2.6 days for the piperacillin/tazobactam and imipenem/cilastatin groups, respectively. No statistical significance was found for the difference in duration of therapy (P = 0.376). Total drug treatment costs were $538.83 +/- $385.33 for the piperacillin/tazobactam group and $687.66 +/- $345.37 for the imipenem/cilastatin group. This difference in treatment cost was statistically significant (P = 0.0001). The need for laboratory tests and the use of other medications were not different between the two groups. Total hospital-days charges were higher for the piperacillin/tazobactam group ($18,339.76 +/- $6090.38) compared with the imipenem/cilastatin group ($16,150.00 +/- $5088.60) (P = 0.052). These findings suggest that length of hospital stay should be the economic focus of antibiotic therapy.

引用

页码：126 / 135

页数：10

共 12 条

[1] Stone, Haney, Kolb, Et al., Prophylactic and preventive antibiotic therapy: Timing, duration and economics, Ann Surg, 189, pp. 691-699, (1979)
[2] Brismar, Malmborg, Tunevall, Et al., Piperacilin-tazobactam versus imipenemcilastatin for treatment of intra-abdominal infections, Antimicrob Agents Chemother, 36, pp. 2766-2773, (1992)
[3] Solomkin, Fant, Rivera, Et al., Randomized trial of imipenem/cilastatin versus gentamicin and clindamycin in mixed flora infection, The American Journal of Medicine, 78, pp. 85-91, (1985)
[4] Kager, Nord, Imipenem/cilastatin in the treatment of intraabdominal infection: A review of world experience, Rev Infect Dis, 7, pp. 5518-5521, (1985)
[5] Hackford, Talley, Reinhold, Et al., Prospective study comparing imipenemcilastatin with clindamycin and gentamicin for the treatment of serious surgical infections, Arch Surg, 123, pp. 322-326, (1988)
[6] Uhari, Seppanen, Heikkinen, Imipenem-cilastatin versus tobramycin and metronidazole for appendicitis-related infection, Pediatr Infect Dis J, 11, pp. 445-450, (1992)
[7] Berne, Yellin, Appleman, Et al., A clinical comparison of cefepime and metronidazole versus gentamicin and clindamycin in the antibiotic management of surgically treated advanced appendicitis, Surg Gynecol Obstet, 170, pp. 18-22, (1993)
[8] Paxinos, Hammel, Fritz, Contamination rates and costs associated with the use of four intermittent intravenous infusion systems, Am J Hosp Pharm, 36, pp. 1497-1503, (1979)
[9] Anonymous. Rules and Regulations, Federal Register, 58, 168, (1993)
[10] Rapp, Bannon, Bivins, The influence of dose frequency and agent toxicity on the cost of parenteral antibiotic therapy, Drug Intell Clin Pharm, 16, pp. 935-938, (1982)

← 1 2 →